fasudil has been researched along with Leukemia, Myeloid, Acute in 2 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klaeger, S | 1 |
| Heinzlmeir, S | 1 |
| Wilhelm, M | 1 |
| Polzer, H | 1 |
| Vick, B | 1 |
| Koenig, PA | 1 |
| Reinecke, M | 1 |
| Ruprecht, B | 1 |
| Petzoldt, S | 1 |
| Meng, C | 1 |
| Zecha, J | 1 |
| Reiter, K | 1 |
| Qiao, H | 1 |
| Helm, D | 1 |
| Koch, H | 1 |
| Schoof, M | 1 |
| Canevari, G | 1 |
| Casale, E | 1 |
| Depaolini, SR | 1 |
| Feuchtinger, A | 1 |
| Wu, Z | 1 |
| Schmidt, T | 1 |
| Rueckert, L | 1 |
| Becker, W | 1 |
| Huenges, J | 1 |
| Garz, AK | 1 |
| Gohlke, BO | 1 |
| Zolg, DP | 1 |
| Kayser, G | 1 |
| Vooder, T | 1 |
| Preissner, R | 1 |
| Hahne, H | 1 |
| Tõnisson, N | 1 |
| Kramer, K | 1 |
| Götze, K | 1 |
| Bassermann, F | 1 |
| Schlegl, J | 1 |
| Ehrlich, HC | 1 |
| Aiche, S | 1 |
| Walch, A | 1 |
| Greif, PA | 1 |
| Schneider, S | 1 |
| Felder, ER | 1 |
| Ruland, J | 1 |
| Médard, G | 1 |
| Jeremias, I | 1 |
| Spiekermann, K | 1 |
| Kuster, B | 1 |
| Wermke, M | 1 |
| Camgoz, A | 1 |
| Paszkowski-Rogacz, M | 1 |
| Thieme, S | 1 |
| von Bonin, M | 1 |
| Dahl, A | 1 |
| Platzbecker, U | 1 |
| Theis, M | 1 |
| Ehninger, G | 1 |
| Brenner, S | 1 |
| Bornhäuser, M | 1 |
| Buchholz, F | 1 |
2 other studies available for fasudil and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinas | 2017 |
RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; Apoptosis; Female; Humans; Leu | 2015 |